Figure 7.

SR141716A affected neither acquisition nor extinction of 750 ms interval trace eyeblink conditioning. A, Temporal relationship between CS and US for trace conditioning paradigm with a trace interval of 750 ms. B, C, The effect of CB₁ antagonist on the acquisition of trace conditioning (trace interval of 750 ms) was tested. Data are illustrated similarly to Figure 6, B and C. B, There was no statistically significant difference in CR% between control and SR141716A-injected mice during the acquisition phase. C, The averaged EMG amplitudes of eyeblink response on day 10 for control (gray trace) and SR141716A-treated (black trace) mice showed similar amplitude and patterns. D, E, The effect of CB₁ antagonist on the extinction of trace conditioning (trace interval of 750 ms) was investigated. Data are illustrated similarly to Figure 6, D and E. D, There was no difference in CR% during extinction phase for the two mouse groups. E, The averaged EMG amplitude of eyeblink response for control (gray trace) and SR141716A-treated (black trace) mice on day 11 showed similar amplitude and patterns. Experiments were performed with male C57BL6/J mice at 9–10 weeks of age.